Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
To determine the clinical, hormonal, and biochemical effects of metformin therapy in obese and nonobese patients with polycystic ovary syndrome (PCOS). Controlled clinical study. Department of Gynecology of Federal University of São Paulo, São Paulo, Brazil. Twenty-nine patients with PCOS. Patients were treated with 500 mg of p.o. metformin t.i.d. for 6 months. Clinical data as well as serum concentrations of sex steroids, sex hormone-binding globulin (SHBG), gonadotropins, leptin, GH, lipids, insulin, and glucose levels were assessed before and after treatment. In the metformin group of nonobese patients, the mean fasting serum insulin concentration decreased from a pretreatment value of 12.1 +/- 2.4 to 6.3 +/- 0.6 microU/mL after treatment, and the area under the curve of insulin decreased from 5,189.1 +/- 517.4 to 3,035.6 +/- 208.9 microU/mL per minute. Also in the metformin group of nonobese patients, the mean basal serum total testosterone, free testosterone, and androstenedione concentrations decreased by 38%, 58%, and 30%, respectively. In the obese patients treated with metformin, only free testosterone showed a statistically significant decrease (1.7 +/- 0.2). Our data suggest that nonobese patients respond better than obese patients to a 1.5 g/day metformin regimen.